BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 28753787)

  • 1. In Men with Castration-Resistant Prostate Cancer, Visceral Metastases Predict Shorter Overall Survival: What Predicts Visceral Metastases? Results from the SEARCH Database.
    Whitney CA; Howard LE; Posadas EM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Eur Urol Focus; 2017 Oct; 3(4-5):480-486. PubMed ID: 28753787
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is computed tomography a necessary part of a metastatic evaluation for castration-resistant prostate cancer? Results from the Shared Equal Access Regional Cancer Hospital Database.
    Hanyok BT; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Posadas EM; Freedland SJ
    Cancer; 2016 Jan; 122(2):222-9. PubMed ID: 26484853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of skeletal-related events and mortality in men with metastatic, castration-resistant prostate cancer: Results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Tablazon IL; Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ; Williams SB
    Cancer; 2019 Nov; 125(22):4003-4010. PubMed ID: 31390061
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do skeletal-related events predict overall survival in men with metastatic castration-resistant prostate cancer?
    Howard LE; De Hoedt AM; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Divers CH; Valderrama A; Freedland SJ
    Prostate Cancer Prostatic Dis; 2016 Dec; 19(4):380-384. PubMed ID: 27377207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Race does not predict the development of metastases in men with nonmetastatic castration-resistant prostate cancer.
    Whitney CA; Howard LE; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Terris MK; Freedland SJ
    Cancer; 2016 Dec; 122(24):3848-3855. PubMed ID: 27505036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Impacts of Metastatic Site and Pain on Progression to Castrate Resistance and Mortality in Patients with Metastatic Prostate Cancer.
    Koo KC; Park SU; Kim KH; Rha KH; Hong SJ; Yang SC; Chung BH
    Yonsei Med J; 2015 Sep; 56(5):1206-12. PubMed ID: 26256961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thresholds for PSA doubling time in men with non-metastatic castration-resistant prostate cancer.
    Howard LE; Moreira DM; De Hoedt A; Aronson WJ; Kane CJ; Amling CL; Cooperberg MR; Terris MK; Freedland SJ
    BJU Int; 2017 Nov; 120(5B):E80-E86. PubMed ID: 28371163
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic importance of metastatic site in men with metastatic castration-resistant prostate cancer.
    Pond GR; Sonpavde G; de Wit R; Eisenberger MA; Tannock IF; Armstrong AJ
    Eur Urol; 2014 Jan; 65(1):3-6. PubMed ID: 24120464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Race does not predict skeletal-related events and all-cause mortality in men with castration-resistant prostate cancer.
    Patel DN; Howard LE; De Hoedt AM; Amling CL; Aronson WJ; Cooperberg MR; Kane CJ; Klaassen ZW; Terris MK; Freedland SJ
    Cancer; 2020 Jul; 126(14):3274-3280. PubMed ID: 32374476
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predicting bone scan positivity in non-metastatic castration-resistant prostate cancer.
    Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Hanyok BT; Pratson CL; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Liede A; Freedland SJ
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):333-7. PubMed ID: 26171882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predicting Time From Metastasis to Overall Survival in Castration-Resistant Prostate Cancer: Results From SEARCH.
    Moreira DM; Howard LE; Sourbeer KN; Amarasekara HS; Chow LC; Cockrell DC; Pratson CL; Hanyok BT; Aronson WJ; Kane CJ; Terris MK; Amling CL; Cooperberg MR; Freedland SJ
    Clin Genitourin Cancer; 2017 Feb; 15(1):60-66.e2. PubMed ID: 27692812
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alkaline phosphatase velocity predicts overall survival and bone metastasis in patients with castration-resistant prostate cancer.
    Hammerich KH; Donahue TF; Rosner IL; Cullen J; Kuo HC; Hurwitz L; Chen Y; Bernstein M; Coleman J; Danila DC; Metwalli AR
    Urol Oncol; 2017 Jul; 35(7):460.e21-460.e28. PubMed ID: 28410987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone Scan Index Is an Independent Predictor of Time to Castration-resistant Prostate Cancer in Newly Diagnosed Prostate Cancer: A Prospective Study.
    Zacho HD; Gade M; Mortensen JC; Bertelsen H; Boldsen SK; Barsi T; Petersen LJ
    Urology; 2017 Oct; 108():135-141. PubMed ID: 28760556
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obese patients with castration-resistant prostate cancer may be at a lower risk of all-cause mortality: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database.
    Vidal AC; Howard LE; de Hoedt A; Kane CJ; Terris MK; Aronson WJ; Cooperberg MR; Amling CL; Freedland SJ
    BJU Int; 2018 Jul; 122(1):76-82. PubMed ID: 29521009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quantification of skeletal metastases in castrate-resistant prostate cancer predicts progression-free and overall survival.
    Tait C; Moore D; Hodgson C; Brown M; Morris T; Growcott J; Malone M; Hughes A; Renehan A; Clarke NW; Dive C
    BJU Int; 2014 Dec; 114(6b):E70-E73. PubMed ID: 24589330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of the Charlson comorbidity index and hypertension with survival in men with metastatic castration-resistant prostate cancer.
    Goyal J; Pond GR; Galsky MD; Hendricks R; Small A; Tsao CK; Sonpavde G
    Urol Oncol; 2014 Jan; 32(1):36.e27-34. PubMed ID: 23685020
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate-specific antigen level, stage or Gleason score: which is best for predicting outcomes after radical prostatectomy, and does it vary by the outcome being measured? Results from Shared Equal Access Regional Cancer Hospital database.
    Mithal P; Howard LE; Aronson WJ; Kane CJ; Cooperberg MR; Terris MK; Amling CL; Freedland SJ
    Int J Urol; 2015 Apr; 22(4):362-6. PubMed ID: 25728968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
    Conteduca V; Caffo O; Fratino L; Lo Re G; Basso U; D'Angelo A; Donini M; Verderame F; Ratta R; Procopio G; Campadelli E; Massari F; Gasparro D; Ermacora P; Messina C; Giordano M; Alesini D; Zagonel V; Veccia A; Lolli C; Maines F; De Giorgi U
    Future Oncol; 2015; 11(21):2881-91. PubMed ID: 26436290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase 3 Assessment of the Automated Bone Scan Index as a Prognostic Imaging Biomarker of Overall Survival in Men With Metastatic Castration-Resistant Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial.
    Armstrong AJ; Anand A; Edenbrandt L; Bondesson E; Bjartell A; Widmark A; Sternberg CN; Pili R; Tuvesson H; Nordle Ö; Carducci MA; Morris MJ
    JAMA Oncol; 2018 Jul; 4(7):944-951. PubMed ID: 29799999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
    Halabi S; Kelly WK; Ma H; Zhou H; Solomon NC; Fizazi K; Tangen CM; Rosenthal M; Petrylak DP; Hussain M; Vogelzang NJ; Thompson IM; Chi KN; de Bono J; Armstrong AJ; Eisenberger MA; Fandi A; Li S; Araujo JC; Logothetis CJ; Quinn DI; Morris MJ; Higano CS; Tannock IF; Small EJ
    J Clin Oncol; 2016 May; 34(14):1652-9. PubMed ID: 26951312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.